Clinical Trials Logo

Filter by:
NCT ID: NCT00627926 Completed - Hepatitis C Clinical Trials

A Phase 3 Study of Telaprevir in Combination With Pegasys® and Copegus® in Treatment-Naive Subjects With Genotype 1 Hepatitis C Virus (HCV)

Start date: March 2008
Phase: Phase 3
Study type: Interventional

A Phase 3 study to evaluate the efficacy and safety of two dosing regimens of telaprevir in combination with pegylated interferon alfa 2a (Peg-IFN-alfa-2a) and ribavirin (RBV).

NCT ID: NCT00623649 Completed - HCV Infection Clinical Trials

Safety,Tolerability and Pharmacokinetics of Multiple Ascending Doses of VCH 916 in Subjects With Chronic Hep C Infection

Start date: November 2007
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine whether a 3-day course of therapy with orally administered VCH-916 given at different dosages can effectively reduce the amount of circulating virus (i.e., viral load) in patients with early-stage chronic hepatitis C-infection. This study will also evaluate the safety and tolerability of treatment with VCH-916. Blood samples will also be taken to measure the levels of VCH-916 present in plasma at various time points during the treatment period.

NCT ID: NCT00623428 Completed - Clinical trials for Hepatitis C, Chronic

A Study of Combination Therapy With PEGASYS (Pegylated Interferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response

Start date: June 2008
Phase: Phase 3
Study type: Interventional

This study will evaluate the efficacy and safety of peginterferon alfa-2a 40KD + ribavirin combination therapy given for 24 weeks versus 48 weeks in patients with chronic hepatitis C, genotype 2/3.

NCT ID: NCT00618007 Completed - Clinical trials for Diabetes Mellitus, Type 2

Effect of PF-00734200 in Subjects With Type 2 Diabetes

Start date: February 2008
Phase: Phase 2
Study type: Interventional

To determine the effect of PF-00734200 on HbA1c in type 2 diabetic subjects receiving metformin

NCT ID: NCT00616330 Completed - Vaginitis Clinical Trials

Vaginal Infection Study

Start date: January 2008
Phase: Phase 3
Study type: Interventional

This study will evaluate the efficacy and safety of a vaginal product compared with that of other vaginal products in the treatment of vaginal infections.

NCT ID: NCT00615563 Completed - HIV Infections Clinical Trials

Utilization of HIV Drug Resistance Testing in Treatment Experienced Patients (UTILIZE Study)

Start date: March 2007
Phase: Phase 4
Study type: Observational

The primary objective of this trial was to assess the presence of susceptibility to tipranavir and other ARVs of the HIV-1 isolates in treatment experienced patients. The secondary objective was to examine clinicians' use of HIV drug resistance testing in treatment experienced patients currently failing a PI based HAART regimen.

NCT ID: NCT00614211 Completed - Cervical Cancer Clinical Trials

Laparoscopic Approach to Cervical Cancer

LACC
Start date: January 2008
Phase: N/A
Study type: Interventional

The goal of this clinical research study is to compare the long-term outcomes of different surgical methods for the treatment of cervical cancer. The long-term outcome of a total abdominal radical hysterectomy (TARH) will be compared against laparoscopy. In this study, the laparoscopy will be done with or without robotic technology.

NCT ID: NCT00612586 Completed - Colorectal Cancer Clinical Trials

Study of Enzastaurin With 5-Fluorouracil/Leucovorin (5-FU/LV) Plus Bevacizumab as Maintenance Regimen Following First Line Therapy for Metastatic Colon Cancer

Start date: February 2008
Phase: Phase 2
Study type: Interventional

This study will evaluate the addition of enzastaurin to 5-FU (5-fluorouracil)/LV (leucovorin) plus bevacizumab in the maintenance of best response obtained with 6 cycles of first-line therapy consisting of 5-FU/LV + oxaliplatin (FOLFOX) or 5-FU/LV + irinotecan (FOLFIRI), plus bevacizumab in patients with Metastatic Colorectal Cancer.

NCT ID: NCT00605215 Completed - Multiple Sclerosis Clinical Trials

BRAVO Study: Laquinimod Double-blind Placebo-controlled Study in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) With a Rater Blinded Reference Arm of Interferon β-1a (Avonex®)

BRAVO
Start date: April 24, 2008
Phase: Phase 3
Study type: Interventional

The study aims to compare the effect of daily oral treatment of laquinimod capsules 0.6 milligrams (mg) with the effect of placebo capsules (capsules that contain no active medication) as well as with the effect of an existing Multiple Sclerosis (MS) injectable drug: Interferon β-1a (Avonex®).

NCT ID: NCT00604175 Completed - HIV Infections Clinical Trials

Safety of and Immune Response to the Human Papillomavirus (HPV) Vaccine in HIV-Infected Women

Start date: February 2008
Phase: Phase 2
Study type: Interventional

Human papillomavirus (HPV) is the most common sexually transmitted disease in the world. HPV infection can cause genital warts and certain cervical problems, including cervical cancer. HPV infection may be more severe and harder to treat in HIV-infected people. The purpose of this study was to determine whether the quadrivalent HPV vaccine is safe, tolerable, and effective in producing antibodies to HPV in HIV-infected women.